Investment area
Seed Investments
Bioindustrial Investments
Region
Europe
Date of investment
December 2014
Biosyntia is a biotech start-up within synthetic biology and metabolic engineering. The company develops microbial biocatalysts at an unprecedented speed and efficiency by employing its patent pending high-throughput screening technology. The pipeline includes the vitamins biotin and thiamine.
Contact
Thomas Grotkjær
Partner
Department: Bioindustrial Investments
Thomas joined Novo Holdings in 2017 and is Partner in the Bioindustrial Investments team where he also oversees the Nordic early-stage activities.
Prior to joining Novo Holdings, Thomas worked in business development at Novozymes where he introduced advanced yeast technology to the biofuel industry and built a portfolio of biochemical projects. Earlier in this career, he was part of the venture capital backed start-up company Fluxome Sciences. He also held positions in biotechnology research and process engineering at Toftejorg (now Alfa Laval) and the Carlsberg Breweries.
Thomas holds a PhD in Metabolic Engineering and a MSc in Chemical Engineering from the Technical University of Denmark as well as graduate diplomas in Business Administration (Marketing Management and Finance) from Copenhagen Business School.
Contact
Søren Møller
Managing Partner
Departments: Life Sciences Operating Committee, Seed Investments
Søren joined Novo A/S in 2011 as Managing Investment Director of Seed Investments.
Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Seed Investments, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).